[시장보고서]피하 생물제제 시장(제5판) : 업계 동향과 세계 예측(-2035년) - 생물제제 유형별, 기본 원리별, 치료 영역별, 약물전달 디바이스별, 지역별, 의약품 판매 예측

피하 생물제제 시장(제5판) : 업계 동향과 세계 예측(-2035년) - 생물제제 유형별, 기본 원리별, 치료 영역별, 약물전달 디바이스별, 지역별, 의약품 판매 예측

Subcutaneous Biologics Market (5th Edition), Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Biologic, Fundamental Principle, Therapeutic Area, Drug Delivery Device, Geographical Regions and Sales Forecast of Drugs

상품코드 : 1849799

리서치사 : Roots Analysis

발행일 : 2025년 10월

페이지 정보 : 영문 997 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,799

￦ 6,933,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999

￦ 10,112,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599

￦ 15,313,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999

￦ 26,004,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

피하 생물제제 시장 : 개요

세계의 피하 생물제제 시장 규모는 현재 2,510억 달러에서 2035년까지 2,330억 달러로 성장할 것으로 예측됩니다.

시장 세분화 및 기회 분석은 다음과 같은 매개 변수로 세분화되어 있습니다.

생물제제 유형

항체
뉴클레오티드
단백질

치료 유형

단독요법
병용요법
둘 다(단독요법과 병용요법)

투여 방법

주사
수액
둘 다(주사와 점적)

기본 원리

인캡슐레이션
복합체 형성
포합
아미노산 상호작용
기타

최종사용자

제약회사 및 바이오 제약회사
생명공학 기업
메디테크 기업
개발 및 제조 수탁기관
교육기관
의료기기 제조업체
기타

결제 방법

마일스톤 지급
계약 일시금

치료 영역

자가면역질환
골질환
혈액 질환
감염성 질환
염증성 질환
대사성 질환
신경질환
안질환
종양학 질환
기타

약물전달 유형

대용량 웨어러블 주사기
자동 주사기
니들 프리 주입 시스템
새로운 약물 재구성 시스템
프리필드 시린지

지역

북미
유럽
아시아태평양
중동 및 북아프리카
라틴아메리카

피하생물의약품 시장 성장 및 동향

최근 수년간 제약업계에서 생물제제에 대한 수요가 증가하고 있습니다. 실제로 업계에서는 미국 식품의약국(USFDA)의 승인을 받은 생물제제의 수가 증가하고 있습니다. 이러한 변화는 생물제제의 정확한 결합과 독특한 대사 경로를 통해 약물 상호 작용을 최소화하고 표적화된 치료를 제공할 수 있는 능력에 기인합니다.

그러나 생물제제 개발에는 여러 가지 어려움이 있습니다. 고분자량, 구조의 복잡성, 투여 후 분해의 용이성, 제조상의 복잡성 등으로 인해 제약회사는 개발을 위해 새로운 기술을 도입해야 하는 상황에 처해 있습니다. 접합법, 아미노산 변형법, 인캡슐레이션법을 이용한 피하 생물제제의 제형화는 이러한 기술 혁신의 일환입니다.

또한 고점도 제제를 투여하기 위해 자동 주사기, 프리필드 시린지, 바늘을 사용하지 않는 방법 등 새로운 약물전달 시스템이 개발되고 있습니다. 이전에는 생물제제는 빠른 전신 분포와 강력한 생체 이용률로 인해 정맥으로 투여되었습니다. 정맥 투여는 효과적이지만, 의료진의 정기적인 투약이 필요한 경우가 많아 복약 순응도에 걸림돌로 작용했습니다. 또한 피하 생물제제로의 전환은 자가 투여 치료의 필요성이 증가하고 자동 주사기, 프리필드 시린지 등 사용하기 쉬운 약물전달 툴의 존재로 인해 가속화되고 있습니다.

피하 생물제제 시장 주요 인사이트

이 보고서는 피하생물의약품 시장의 현황을 살펴보고 업계내 잠재적인 성장 기회를 파악합니다. 이 보고서의 주요 조사 결과는 다음과 같습니다.

현재 175개 이상의 피하 생물제제가 다양한 만성질환 치료제로 승인되었으며, 이 중 약 50%가 1일 1회 투여하는 단백질 제제로 승인되었습니다.

2020년 이후 승인된 피하생물의약품의 약 20%가 2020년 이후 승인되었으며, 그 중 대부분은 단독투여가 가능한 항체입니다.
340개 이상의 피하생물의약품이 임상개발 단계에 있으며, 이들 생물제제의 10%는 희귀질환치료제로 지정된 항체입니다.

임상 단계에 있는 피하 생물제제의 약 60%는 억제 메커니즘에 기반하고 있으며, 흥미롭게도 이들 생물제제의 대부분은 단독 요법이 가능합니다.
약 20%에 가까운 기술이 인캡슐레이션 원리를 기반으로 하고 있으며, 특히 이들 기술은 모두 약물 방출의 연장/제어/지속성에 초점을 맞추었습니다.
이 분야에 대한 관심 증가는 제휴 활동의 활성화에도 반영되어, 실제로 지난 3년간 거래의 70% 가까이가 체결된 것으로 나타났습니다.
피하 투여를 용이하게 하는 새롭고 혁신적인 약물전달 시스템은 여러 가지가 있으며, 현재 사용 가능하거나 개발중인 시스템은 560개 이상입니다.
환자의 순응도 및 치료 결과 개선에 대한 관심이 높아짐에 따라 승인된 피하생물의약품 시장은 2027년까지 연평균 5%의 성장률을 보일 것으로 예측됩니다.

피하 제제 기술이 제공하는 수많은 장점과 라이선스 계약 증가로 인해 향후 10년간 연평균 22.7%의 성장률을 보일 것으로 예측됩니다.

피하 생물제제 시장 주요 부문

승인된 피하생물의약품 시장

항체가 시장에서 가장 높은 점유율을 차지

생물제제 유형에 따라 승인된 피하 생물제제 세계 시장은 항체, 뉴클레오티드, 단백질로 구분됩니다. 현재 항체가 시장에서 가장 높은 점유율을 차지하고 있는 이유는 높은 표적 특이성, 높은 안전성, 낮은 독성 때문입니다. 또한 뉴클레오티드 승인 피하 생물제제 시장은 예측 기간 중 상당한 성장을 보일 것으로 예측됩니다.

단독요법과 병용요법 모두에서 높은 시장 점유율 확보

승인된 피하생물의약품 세계 시장은 단독요법, 병용요법, 단독요법 및 병용요법으로 구분됩니다. 단독요법과 병용요법 부문이 현재 가장 큰 시장 점유율을 차지하고 있으며, 예측 기간 중 큰 폭의 성장이 예상됩니다.

주사제가 승인된 피하 생물제제 시장 점유율의 대부분을 차지하고 있습니다.

이 부문에서는 주사, 점적, 주사 및 점적 모두와 같은 다양한 투여 방법 유형별로 승인된 피하 생물제제 세계 시장 분포를 밝힙니다. 현재 승인된 피하 생물의약품 시장 점유율은 대부분 주사제가 차지하고 있으며, 예측 기간 중도 주사제가 지배적일 것으로 예측됩니다. 이는 주사로 투여하는 것이 환자뿐만 아니라 의료 전문가에게도 더 편리하다는 사실에 기인합니다. 또한 알레르기 반응이나 체액 과다의 가능성도 감소합니다.

자가면역질환 분야가 피하생물의약품 시장에서 가장 높은 점유율을 차지하고 있습니다.

승인된 피하생물의약품 세계 시장은 치료 영역별로 자가면역질환, 대사질환, 종양질환, 혈액질환, 염증성질환, 신경질환, 골질환, 기타 질환으로 구분됩니다. 현재 피하생물의약품 시장에서 가장 높은 점유율을 차지하고 있는 것은 자가면역질환입니다. 이는 주로 건선, 강직성 척추염, 궤양성 대장염, 크론병 등 다양한 유행성 자가면역질환의 치료에서 이 약물의 효능이 높기 때문입니다. 그러나 예측 기간 중 당뇨병 및 비만 환자(약물의 장기 투여가 필요한 환자)에 대한 피하주사 선호도가 높아짐에 따라 대사성 질환 분야가 더 큰 시장 점유율을 차지할 것으로 보입니다.

북미가 전체 시장의 대부분을 차지할 것으로 예상

이 분야에서는 북미, 유럽, 아시아태평양, 중동 및 북아프리카, 라틴아메리카 등 다양한 지역에 걸쳐 승인된 피하 생물제제 시장의 분포를 밝힙니다. 당사의 예측에 따르면 현재 북미가 전체 시장의 대부분(-50%)을 차지하고 있습니다. 또한 아시아태평양 시장은 2035년까지의 예측 기간 중 상대적으로 높은 CAGR로 성장할 것으로 예측됩니다. 아시아태평양 시장의 성장은 환자 인구의 급증, 만성질환(신경질환, 유전질환, 자가면역질환 등)의 유병률 증가, 효과적이고 진보된 치료제에 대한 수요 증가에 기인합니다. 또한 환자와 의사들 사이에서 생물제제의 채택을 촉진하기 위해 아시아 국가의 규제기관이 투자 및 구상을 늘리는 것은 향후 시장을 주도할 가능성이 높습니다.

피하생물의약품 제제기술 시장

기본원리별 시장 점유율

세계 피하 생물제제화 기술 시장은 아미노산 상호 작용, 복합체 형성, 접합, 아미노산 상호 작용, 인캡슐레이션, 기타 기본 원리 등 다양한 기본 원리에 따라 분류됩니다. 현재 인캡슐레이션 원리에 기반한 기술 라이선싱을 통한 매출이 전체 시장의 대부분을 차지하고 있으며, 예측 기간 중도 지배적인 위치를 유지할 것으로 보입니다. 인캡슐레이션는 소수성인 생물제제의 용해도를 높이는 데 도움이 되며, 그 결과 환자의 체내 약물 흡수율이 높아진다는 점은 주목할 만합니다. 또한 약물의 인캡슐레이션는 높은 표적 특이성으로 이어져(일반적으로 전신 노출이 많기 때문에 발생하는) 부작용의 가능성도 감소시킵니다.

생명공학 기업은 비교적 높은 CAGR로 성장할 것으로 추정됩니다.

세계 피하생물의약품 제제 기술 시장은 생명공학 기업, 개발 및 제조 위탁기관, 교육기관, 의료기기 제조업체, MedTech 기업, 제약 및 바이오제약 기업, 기타 최종사용자 등 다양한 최종사용자를 대상으로 하고 있습니다. 특히 제약 및 바이오 제약 기업이 현재 시장에서 가장 높은 점유율을 차지하고 있지만, 시장 추정 및 예측 기간 중 생명공학 기업이 상대적으로 높은 CAGR로 성장할 것으로 예측됩니다.

피하 기술 시장에서 가장 큰 점유율을 차지하는 종양성 질환

이 부문에서는 자가면역질환, 골질환, 혈액질환, 감염질환, 염증성 질환, 대사성 질환, 신경질환, 안질환, 종양질환, 기타 질환 등 다양한 치료 분야에 걸친 세계 피하생물의약품 제제 기술 시장의 분포를 파악할 수 있습니다. 현재 기술 시장에서 암 질환이 가장 큰 비중을 차지하고 있다는 점은 주목할 만합니다. 이는 종양성 질환의 발병률이 높아 2022년에는 약 190만 건, 2023년에는 200만 건 이상을 차지할 것으로 예상되기 때문입니다. 또한 자가면역질환을 위한 피하 생물제제 기술 세계 시장은 예측 기간 중 가장 높은 CAGR로 성장할 것으로 예측됩니다.

아시아태평양 피하 생물제제 기술 시장, 가장 높은 CAGR로 성장할 것으로 예측됩니다.

이 분야에서는 북미, 유럽, 아시아태평양 등 다양한 지역의 피하생물의약품 제제 기술 시장의 분포를 밝힙니다. 북미가 현재 전 세계 피하생물의약품 제제 기술 시장의 65% 가량을 차지하고 있다는 점은 주목할 만합니다. 또한 아시아태평양의 피하 생물제제 기술 시장은 예측 기간 중 가장 높은 CAGR로 성장할 것으로 예측됩니다. 아시아태평양 시장 성장은 이 지역의 기술 개발자들이 제약회사와의 라이선싱 계약에 적극적으로 참여하고 있기 때문인 것으로 분석됩니다.

마일스톤 지급이 주요 점유율을 차지합니다.

세계 피하제제 기술 시장은 마일스톤 지불과 계약 일시금 지불로 구분됩니다. 현재 시장에서는 마일스톤 결제가 대부분을 차지하고 있으며, 이러한 추세는 앞으로도 변하지 않을 것으로 보입니다.

피하생물의약품 시장 진출기업 사례

Adocia
Alteogen
Ascendis Pharma
CD Bioparticles
Creative Biolabs
Creative BioMart
Foresee Pharmaceuticals
Pacira Biosciences
The Wyss Institute
Xeris Biopharma

1차 조사 개요

본 시장 보고서에 수록된 의견과 인사이트는 업계 이해관계자들과의 논의를 통해 영향을 받았습니다. 이 보고서에는 다음과 같은 업계 이해관계자들과의 심층 인터뷰 기록이 수록되어 있습니다.

미국,소규모 기업,설립자 겸 CEO,미국
영국,중견기업,창업자 겸 최고기술책임자,영국
미국,소규모 기업,CEO 겸 창업자,미국
덴마크,중소기업,최고 경영자,덴마크,CEO
미국,중견기업,최고 경영자,CEO
인도,대기업,최고기술경영자,인도,최고기술책임자
이스라엘,대기업,부사장 겸 최고과학자,이스라엘,수석과학자
미국,대기업,수석 포트폴리오 디렉터,미국
오스트리아,소기업,전무이사,오스트리아,중소기업,경영자
프랑스,중견기업,커뮤니케이션 리더,프랑스,커뮤니케이션 리더
미국,중견기업,전 설립자 겸 최고 과학 책임자,부사장 겸 제품 개발,전 제약 수석 과학자
독일,대기업,전직 최고 광고 책임자,전 최고 광고 책임자
미국 기업,익명
유럽기업,익명

피하생물의약품 시장 조사 대상

시장 규모와 기회 분석 이 보고서에서는 세계 피하 생물제제 시장을(A) 1차 포장 용기 유형,(B) 생물제제 유형,(C) 치료 유형,(D) 투여 방법,(E) 기본 원리,(F) 최종사용자,(G) 지불 방법,(H) 치료 분야,(I) 약물전달 장치 유형,(J) 지역 등 주요 부문별로 분석합니다. 유형,(J) 지역 등 주요 시장 부문에 대한 철저한 분석이 이루어지고 있습니다.
시장 상황: A)설립연도, B)기업 규모, C)본사 소재지, D)시장 개발 현황, E)생물제제의 유형, F)치료 유형, G)작용기전, H)투여 빈도, I)대상 질환 적응증, J)치료 영역, K)의약품명 등 관련 파라미터를 기반으로 피하 생물제제 시장과 관련된 기업을 상세하게 평가.
기술 현황: A) 설립연도, B) 기업 규모, C) 본사 소재지, D) 기본 이념, E) 분자 유형, F) 투여 경로, G) 치료 영역, H) 주요 특성 등 여러 관련 파라미터를 기반으로 피하생물의약품 시장의 피하생물의약품 기술 현황을 상세하게 평가합니다.
기술경쟁력 분석 :(A) 기업력,(B) 기술력 등의 매개변수를 기반으로 한 피하제제 기술의 종합적인 분석.
기업 개요:(A) 기업 개요,(B) 재무 정보(가능한 경우),(C) 서비스 포트폴리오,(D) 제조 시설,(E) 최근 동향 및 정보에 기반한 미래 전망 등의 매개 변수에 초점을 맞춘 피하 시장에 종사하는 북미, 유럽, 아시아태평양에 기반을 둔 주요 피하 제제 기술 개발 회사의 상세한 프로파일.
파트너십 및 협업 A) 파트너십 체결 연도,(B) 파트너십 유형,(C) 파트너 기업 유형 등의 매개 변수를 기반으로 이 영역에서 보고된 파트너십 활동에 대한 상세한 분석.
SWOT 분석 : 피하생물의약품 시장의 전반적인 발전에 영향을 미칠 것으로 예상되는 SWOT 분석에 따라 업계 관련 동향, 기회, 과제에 대한 심층적인 인사이트를 제공합니다.

챕터 개요
조사 방법
승인된 주요 피하 생물제제 성공 프로토콜 분석
- 벤리스타 R(인간 게놈 사이언스)
- BESREMi(R)(PharmaEssentia)
- COSENTYX(R) (Novartis)
- DARZALEX FASPRO(R) / DARZALEX(R) SC (Halozyme)
- DUPIXENT(R) (Regeneron Pharma)
- Enbrel(R) (Amgen)
- HEMLIBRA(R) (Roche)
- Prolia(R) / Pralia(R) (Amgen)
- STELARA(R) (Janssen Biotech)
- Trulicity(R) (Eli Lilly)
결론

제9장 임상 단계 피하 생물제제 : 시장 구도

챕터 개요

제9장 2.임상 단계 피하 투여 생물제제 : 시장 개요

개발 단계별 분석
생물제제의 유형별 분석
치료법별 분석
작용기서별 분석
투여 빈도별 분석
의약품 지정별 분석
대상 질환 적응증별 분석
치료 영역별 분석

임상 단계 피하 투여 생물제제 : 개발 기업 리스트

제10장 피하 제제 : 테크놀러지 상황

챕터 개요
피하 제제 : 기술 상황
- 기본 원리별 분석
- 분자 유형별 분석
- 투여 경로별 분석
- 치료 영역별 분석
- 주요 특성별 분석
피하 제제 : 기술개발자의 상황

제11장 기술 경쟁력 분석

챕터 개요
전제와 주요 파라미터
조사 방법
기술 경쟁력 분석 : 피하 제제 기술
- 북미에 기반을 둔 기업이 개발한 피하 제제 기술(피어 그룹 I)
- 유럽에 기반을 둔 기업이 개발한 피하 제제 기술(피어 그룹 II)
- 아시아태평양에 기반을 둔 기업이 개발한 피하 제제 기술(피어 그룹 III)

제12장 피하 제제 기술 프로바이더 : 기업 개요

챕터 개요
북미에 기반을 둔 기술개발 업자

CD Bioparticles
Creative Biolabs
Creative BioMart
Pacira BioSciences
The Wyss Institute
Xeris Biopharma

유럽에 기반을 둔 기술개발 업자

Adocia
Ascendis Pharma

아시아태평양에 기반을 둔 기술개발 업자

Alteogen
Foresee Pharmaceuticals

제13장 피하 제제 기술 : 파트너십과 협력

챕터 개요
파트너십 모델
파트너십과 협업 : 피하 제제 기술
지역별 분석

제14장 피하 약물전달 시스템 : 시장 구도

챕터 개요
피하 약물전달 시스템 유형
- 대용량 웨어러블 인젝터
- 오토인젝터
- 펜형 주사기
- 니들 프리 주사 시스템
- 새로운 약제 재구성 전달 시스템
- 프리필드 시린지
- 임플란트

제15장 피하 약물전달 시스템 : 제품 경쟁력 분석

챕터 개요
대용량 웨어러블 인젝터
오토인젝터
니들 프리 주사 시스템
프리필드 시린지

제16장 SWOT 분석

제17장 세계의 승인된 피하 생물제제 시장

제18장 승인된 피하 생물제제 시장(생물제제 유형별)

제19장 승인된 피하 생물제제 시장(치료 유형별)

제20장 승인된 피하 생물제제 시장(투여 방법별)

제21장 승인된 피하 생물제제 시장(치료 영역별)

제22장 승인된 피하 생물제제 시장(지역별)

제23장 승인된 피하 생물제제 시장, 의약품 판매 예측

챕터 개요
주요 전제와 조사 방법
의약품별 판매 예측

제24장 승인된 피하 생물제제 시장(주요 기업별)

제25장 세계의 피하 생물제제 기술 시장

제26장 피하 생물제제 제제 기술 시장(기본 원리별)

제27장 피하 생물제제 제제 기술 시장(최종사용자별)

제28장 피하 생물제제 제제 기술 시장(치료 영역별)

제29장 피하 생물제제 제제 기술 시장(주요 지역별)

제30장 피하 생물제제 제제 기술 시장(결제방법별)

제31장 피하 생물제제 제제 기술 시장, 주요 기업별

제32장 피하 약물전달 시스템 : 시장 예측

제33장 결론

제34장 이그제큐티브 인사이트

제35장 부록 1 : 표형식 데이터

제36장 부록 2 : 기업·단체 리스트

KSA

영문 목차

영문목차

Subcutaneous Biologics Market: Overview

As per Roots Analysis, the global subcutaneous biologics market is estimated to grow from USD 251 billion in the current year to USD 233 billion by 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Biologic

Antibodies
Nucleotides
Proteins

Type of Therapy

Monotherapies
Combination Therapies
Both (Monotherapies and Combination Therapies)

Method of Administration

Injection
Infusion
Both (Injection and Infusion)

Fundamental Principle

Encapsulation
Complex Formation
Conjugation
Amino acid Interaction
Other Fundamental Principles

End User

Pharmaceutical and Biopharmaceutical Companies
Biotechnology Companies
MedTech Companies
Contract Development and Manufacturing Organizations
Educational Institutes
Medical Equipment Manufacturers
Other End Users

Payment Method Employed

Milestone Payments
Upfront Payments

Therapeutic Area

Autoimmune Disorders
Bone Disorders
Hematological Disorders
Infectious Diseases
Inflammatory Disorders
Metabolic Disorders
Neurological Disorders
Ocular Disorders
Oncological Disorders
Other Disorders

Type of Drug Delivery Device

Large Volume Wearable Injectors
Autoinjectors
Needle-free Injection System
Novel Drug Reconstitution System
Prefilled Syringes

Geographical Regions

North America
Europe
Asia-Pacific
Middle East and North Africa
Latin America

Subcutaneous Biologics Market: Growth and Trends

The demand of biologics has risen in the recent years in the pharmaceutical industry. In fact, the industry has witnessed a rise in the number of biologic drugs approved by the USFDA. This shift is due to the ability of biologics to offer targeted treatment, enabling minimal drug interactions owing to their precise binding and unique metabolic pathways.

However, developing biologics involves various challenges. These include high molecular weight, structure complexity susceptibility to degradation after administration, and productional complexities have prompted pharmaceutical companies to adopt new technologies for their development. Formulating subcutaneous biologics via conjugation, amino acid modification, and encapsulation methods are some of these technological innovations.

Additionally, novel drug delivery systems, including autoinjectors, pre-filled syringes, and needle-free methods, have been developed to administer highly viscous formulations. Previously, biologics were administered intravenously because of their swift systemic distribution and strong bioavailability. Although intravenous administration is effective, it frequently necessitates regular administration by healthcare providers, creating a hurdle for medication adherence. In recent years, methods and devices for subcutaneous administration have become increasingly popular among healthcare practitioners due to their effectiveness, safety, and tolerability Moreover, the shift towards subcutaneous biologics is fueled by the increasing need for self-administered treatments and the presence of easy-to-use drug delivery tools such as autoinjectors and pre-filled syringes.

Subcutaneous Biologics Market: Key Insights

The report delves into the current state of the subcutaneous biologics market and identifies potential growth opportunities within industry. Some key findings from the report include:

Presently, more than 175 subcutaneous biologics have been approved for the treatment of various chronic disorders; around 50% of these biologics are proteins approved for once daily administration.

~20% of the subcutaneous biologics have been approved post-2020, majority of which are antibodies that can be administered as monotherapy alone.
More than 340 subcutaneous biologics are in clinical-stages of development; ~10% of these biologics are antibodies that have received orphan drug designation.

Around 60% of the clinical-stage subcutaneous biologics are based on inhibition mechanism; interestingly, majority of these biologics can be administered as monotherapy alone.
Close to 20% of technologies are based on encapsulation principle; notably, all these technologies are focused towards providing extended / controlled / sustained drug release
The rising interest in this domain is reflected by the rise in partnership activity; in fact, close to 70% of the deals were inked in the last three years.
There are several new and innovative drug delivery systems that facilitate subcutaneous administration; we identified over 560 such systems that are presently available / under development.
Driven by the increased emphasis towards patient compliance and improved treatment outcome, the approved subcutaneous biologics market is likely to grow at a CAGR of ~5%, till 2027.

Owing to the numerous advantages offered by subcutaneous formulation technologies and increase in the number of licensing deals, the market is anticipated to grow at an annualized rate of 22.7% in the coming decade.

Subcutaneous Biologics Market: Key Segments

Approved Subcutaneous Biologics Market

Antibodies Occupy the Highest Share in the Market

Based on type of biologic, the global market for approved subcutaneous biologics is segmented into antibodies, nucleotides and proteins. It is worth mentioning that, currently, antibodies occupy the highest share in the market, attributing to its higher target specificity, increased safety profile and lower toxicity. Further, approved subcutaneous biologics market for nucleotides is expected to witness substantial growth during the forecast period.

The Highest Market Share is Captured by Both Monotherapy and Combination Therapies

The global market for approved subcutaneous biologics is segmented across monotherapy, combination therapy, and both monotherapy and combination therapies. Both monotherapy and combination therapies segments occupy the largest current market share and is expected to witness a substantial growth during the forecast period.

Majority of the Approved Subcutaneous Biologics Market Share is Occupied by Injection

This segment highlights the distribution of global market for approved subcutaneous biologics across different types of methods of administration, such as injection, infusion, and both injection and infusion. It is worth highlighting that, presently, majority of the approved subcutaneous biologics market share is occupied by injection as a method of administration and is expected to remain dominant, during the forecast period. This can be attributed to the fact that delivery via injections is more convenient for the patients as well as healthcare professionals. Additionally, the chances of any allergic reaction and fluid overload are also reduced.

Autoimmune Disorders Segment Occupies the Highest Subcutaneous Biologics Market Share

Based on therapeutic area, the global market for approved subcutaneous biologics is segmented into autoimmune disorders, metabolic disorders, oncological disorders, hematological disorders, inflammatory disorders, neurological disorders, bone disorders and other disorders. Currently, autoimmune disorders segment occupies the highest subcutaneous biologics market share. This can be primarily attributed to the high efficacy of these drugs in the treatment of various prevalent autoimmune disorders, such as psoriasis, ankylosing spondylitis, ulcerative colitis and Crohn's disease. However, during the forecast period, metabolic disorders segment is likely to capture a larger market share owing to the rising preference of subcutaneous injection for the administration in patients suffering from diabetes mellitus and obesity (wherein long-term administration of drugs is required).

North America is Likely to Capture a Majority Share in the Overall Market

This segment highlights the distribution of approved subcutaneous biologics market across various geographies, such as North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. According to our projections, presently, North America is likely to capture a majority share (~50%) in the overall market. Further, it is worth highlighting that the market in Asia-Pacific is expected to grow at a relatively higher CAGR, during the forecast period, till 2035. The growth of the market in Asia-Pacific can be ascribed to the rapidly growing patient population, the rising incidence of chronic disorders (including neurological disorders, genetic disorders and autoimmune disorders), and the rising demand for effective and advanced therapeutics. Further, the increasing investments and initiatives taken by regulatory bodies in the Asian countries to promote the adoption of biologics among patients and physicians is likely to drive the market in future.

Subcutaneous Biologics Market for Formulation Technologies

Market Share by Fundamental Principle

The global subcutaneous biologics formulation technology market is segmented across various fundamental principles, such as amino acid interaction, complex formation, conjugation, amino acid interaction, encapsulation and other fundamental principles. Presently, the revenues generated through the licensing of technologies that are based on encapsulation principle are likely to capture majority share in the overall market and is expected to remain dominant during the forecast period. It is worth highlighting that encapsulation helps in increasing the solubility of the biologics that are hydrophobic, which further results in increased absorption of the drugs in the patient's body. Further, drug encapsulation also leads to high target specificity, thereby reducing the likelihood of adverse effects (that usually occur due to high systemic exposure).

Biotechnology Companies are Estimated to Grow at a Relatively Higher CAGR

The global subcutaneous biologics formulation technology market caters to a wide variety of end users, including biotechnology companies, contract development and manufacturing organizations, educational institutes, medical equipment manufacturers, MedTech companies, pharmaceutical and biopharmaceutical companies and other end users. Notably, pharmaceutical and biopharmaceutical companies are expected to currently capture the highest share in the market, However, biotechnology companies are estimated to grow at a relatively higher CAGR, during the forecast period.

Oncological Disorders Hold the Largest Share in the Subcutaneous Technology Market

This segment highlights the distribution of global subcutaneous biologics formulation technology market across different therapeutic areas, such as autoimmune disorders, bone diseases, hematological disorders, infectious diseases, inflammatory disorders, metabolic disorders, neurological disorders, ocular disorders, oncological disorders and other disorders. It is worth highlighting that the oncological disorders hold the largest share in the current technology market. This can be attributed to the high incidence rate of oncological disorders, accounting for around 1.9 million cases in 2022 and over 2 million cases in 2023. Further, the global subcutaneous biologics market for formulation technology for autoimmune disorders is estimated to grow at the highest CAGR, during the forecast period.

Subcutaneous Biologics Formulation Technology Market in Asia-Pacific is Expected To Grow with the Highest CAGR

This segment highlights the distribution of subcutaneous biologics formulation technology market across various geographies, such as North America, Europe and Asia-Pacific. It is worth highlighting that North America captures close to 65% of the current global subcutaneous biologics market for formulation technology. Further, the subcutaneous biologics formulation technology market in Asia-Pacific is expected to grow with the highest CAGR, during the forecast period. The growth of market in Asia-Pacific can be attributed to the rise in number of technology developers in this region, that will be actively involved in inking licensing deals with the drug developers.

Milestone Payments Occupy the Majority Share

Based on payment method employed, the global subcutaneous formulation technology market is segmented into milestone payments and upfront payments. It is worth mentioning that milestone payments occupy the majority share in the current market and this trend is unlikely to change in the future.

Example Players in the Subcutaneous Biologics Market

Adocia
Alteogen
Ascendis Pharma
CD Bioparticles
Creative Biolabs
Creative BioMart
Foresee Pharmaceuticals
Pacira Biosciences
The Wyss Institute
Xeris Biopharma

Primary Research Overview

The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

Founder and Chief Executive Officer, Small Company, US
Founder and Chief Technology Officer, Mid-sized Company, UK
Chief Executive Officer & Founder, Small Company, US
Chief Executive Officer, Small Company, Denmark
Chief Executive Officer, Mid-sized Company, US
Chief Technical Officer, Very Large Company, India
Vice President and Chief Scientist, Large Company, Israel
Senior Portfolio Director, Large Company, US
Managing Director, Small Company, Austria
Communication Leader, Mid-sized Company, France
Former Founder and Chief Scientific Officer, Vice President and Product Development, Former Senior Scientist Formulation, Mid-sized Company, US
Former Chief Commercial Officer, Large Company, Germany
Anonymous, a US-based company
Anonymous, a Europe-based company

Subcutaneous Biologics Market: Research Coverage

Market Sizing and Opportunity Analysis: The report features a thorough analysis of the global subcutaneous biologics market, in terms of the key market segments, including [A] type of primary packaging container, [B] type of biologic, [C] type of therapy, [D] method of administration, [E] fundamental principle, [F] end-user, [G] payment method employed, and [H] therapeutic area, [I] type of drug delivery device and [J] geographical regions.
Market Landscape: An in-depth assessment of the companies involved in the subcutaneous biologics market, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] status of development, [E]type of biologic, [F] type of therapy, [G] mechanism of action, [H] dosing frequency, [I] target disease indication, [J] therapeutic area and [K] drug designation.
Technology Landscape: An in-depth assessment of the landscape of subcutaneous formulation technologies in the subcutaneous biologics market, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] as fundamental principle, [E] type of molecule, [F] route of administration, [G] therapeutic area and [H] key characteristics.
Technology Competitive Analysis: A comprehensive analysis of subcutaneous formulation technologies based on parameters, such as [A] company strength and [B] technology strength.
Company Profiles: In-depth profiles of leading subcutaneous formulation technology developers based in North America, Europe and Asia-Pacific engaged in the subcutaneous market, focused on parameters such as [A] company overview, [B] financial information (if available), [C] service portfolio, [D] manufacturing facilities and [E] recent developments and an informed future outlook.
Partnerships and Collaborations: An in-depth analysis of the partnership's activity reported in this domain, based on parameters such as [A] year of partnership, [B] type of partnership [C] type of partner company.
SWOT Analysis: Deep insights on industry affiliated trends, opportunities and challenges, under SWOT analysis, which are anticipated to impact the overall evolution of the subcutaneous biologics market.

Key Questions Answered in this Report

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
- 2.2.1. Market Landscape and Market Trends
- 2.2.2. Market Forecast and Opportunity Analysis
2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
2.4. Project Methodology
- 2.4.1. Secondary Research
  - 2.4.1.1. Annual Reports
  - 2.4.1.2. Academic Research Papers
  - 2.4.1.3. Company Websites
  - 2.4.1.4. Investor Presentations
  - 2.4.1.5. Regulatory Filings
  - 2.4.1.6. White Papers
  - 2.4.1.7. Industry Publications
  - 2.4.1.8. Conferences and Seminars
  - 2.4.1.9. Government Portals
  - 2.4.1.10. Media and Press Releases
  - 2.4.1.11. Newsletters
  - 2.4.1.12. Industry Databases
  - 2.4.1.13. Roots Proprietary Databases
  - 2.4.1.14. Paid Databases and Sources
  - 2.4.1.15. Social Media Portals
  - 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
  - 2.4.2.1. Types of Primary Research
    - 2.4.2.1.1. Qualitative Research
    - 2.4.2.1.2. Quantitative Research
    - 2.4.2.1.3. Hybrid Approach
  - 2.4.2.2. Advantages of Primary Research
  - 2.4.2.3. Techniques for Primary Research
    - 2.4.2.3.1. Interviews
    - 2.4.2.3.2. Surveys
    - 2.4.2.3.3. Focus Groups
    - 2.4.2.3.4. Observational Research
    - 2.4.2.3.5. Social Media Interactions
  - 2.4.2.4. Key Opinion Leaders Considered in Primary Research
    - 2.4.2.4.1. Company Executives (CXOs)
    - 2.4.2.4.2. Board of Directors
    - 2.4.2.4.3. Company Presidents and Vice Presidents
    - 2.4.2.4.4. Research and Development Heads
    - 2.4.2.4.5. Technical Experts
    - 2.4.2.4.6. Subject Matter Experts
    - 2.4.2.4.7. Scientists
    - 2.4.2.4.8. Doctors and Other Healthcare Providers
  - 2.4.2.5. Ethics and Integrity
    - 2.4.2.5.1. Research Ethics
    - 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools and Databases

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (TAM)
- 3.3.2. Serviceable Addressable Market (SAM)
- 3.3.3. Serviceable Obtainable Market (SOM)
- 3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Key Market Segmentation
3.7. Robust Quality Control
3.8. Limitations

4. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

4.1. Chapter Overview
4.2. Market Dynamics
- 4.2.1. Time Period
  - 4.2.1.1. Historical Trends
  - 4.2.1.2. Current and Future Estimates
- 4.2.2. Currency Coverage and Foreign Exchange Rate
  - 4.2.2.1. Major Currencies Affecting the Market
  - 4.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
  - 4.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
  - 4.2.2.4. Strategies for Mitigating Foreign Exchange Risk
- 4.2.3. Trade Policies
  - 4.2.3.1. Impact of Trade Barriers on the Market
  - 4.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
- 4.2.4. Recession
  - 4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
  - 4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
- 4.2.5. Inflation
  - 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 4.2.5.2. Potential Impact of Inflation on the Market Evolution

5. EXECUTIVE SUMMARY

6. INTRODUCTION

6.1. Chapter Overview
6.2. Types of Therapeutic Molecules
6.3. Biologically Derived Molecules
- 6.3.1. Type of Products
- 6.3.2. Routes of Administration and Formulations
- 6.3.3. Subcutaneous Formulations
  - 6.3.3.1. Approaches in Subcutaneous Delivery of Biologics
    - 6.3.3.1.1. Reformulation
    - 6.3.3.1.2. Differing Potencies
    - 6.3.3.1.3. Novel Technologies
  - 6.3.3.2. Methods of Subcutaneous Administration
  - 6.3.3.3. Advantages of Subcutaneous Administration
  - 6.3.3.4. Limitations of Subcutaneous Administration
6.4. Regulatory Considerations
- 6.4.1. Medical Devices
- 6.4.2. Drug Device Combination Products
6.5. Future Perspectives

7. APPROVED SUBCUTANEOUS BIOLOGICS: MARKET LANDSCAPE

7.1. Chapter Overview

7.2. Approved Subcutaneous Biologics: Overall Market Overview

7.2.1. Analysis by Initial Approval Year
7.2.2. Analysis by Type of Biologic
7.2.3. Analysis by Type of Therapy
7.2.4. Analysis by Route of Administration
7.2.5. Analysis by Method of Administration
7.2.6. Analysis by Dosing Frequency
7.2.7. Analysis by Concentration of Dose
7.2.8. Analysis by Target Disease Indication
7.2.9. Analysis by Therapeutic Area
7.2.10. Analysis by Type of Drug Delivery Device

7.3. Approved Subcutaneous Biologics: List of Developers
- 7.3.1. Analysis by Year of Establishment
- 7.3.2. Analysis by Company Size
- 7.3.3. Analysis by Location of Headquarters (Region)
- 7.3.4. Analysis by Location of Headquarters (Country)
- 7.3.5. Most Active Developers: Analysis by Number of Approved Drugs

8. APPROVED SUBCUTANEOUS BIOLOGICS: SUCCESS PROTOCOL ANALYSIS

8.1. Chapter Overview
8.2. Methodology
8.3. Success Protocol Analysis of Top Approved Subcutaneous Biologics
- 8.3.1. BENLYSTA(R) (Human Genome Sciences)
  - 8.3.1.1. Overview
  - 8.3.1.2. Development History
  - 8.3.1.3. Phase of Development, Route of Administration, and Target Disease Indication
  - 8.3.1.4. Success Protocol Analysis
- 8.3.2. BESREMi(R) (PharmaEssentia)
  - 8.3.2.1. Overview
  - 8.3.2.2. Development History
  - 8.3.2.3. Phase of Development, Route of Administration, and Target Disease Indication
  - 8.3.2.4. Success Protocol Analysis
- 8.3.3. COSENTYX(R) (Novartis)
  - 8.3.3.1. Overview
  - 8.3.3.2. Development History
  - 8.3.3.3. Phase of Development, Route of Administration, and Target Disease Indication
  - 8.3.3.4. Success Protocol Analysis
- 8.3.4. DARZALEX FASPRO(R) / DARZALEX(R) SC (Halozyme)
  - 8.3.4.1. Overview
  - 8.3.4.2. Development History
  - 8.3.4.3. Phase of Development, Route of Administration, and Target Disease Indication
  - 8.3.4.4. Success Protocol Analysis
- 8.3.5. DUPIXENT(R) (Regeneron Pharma)
  - 8.3.5.1. Overview
  - 8.3.5.2. Development History
  - 8.3.5.3. Phase of Development, Route of Administration, and Target Disease Indication
  - 8.3.5.4. Success Protocol Analysis
- 8.3.6. Enbrel(R) (Amgen)
  - 8.3.6.1. Overview
  - 8.3.6.2. Development History
  - 8.3.6.3. Phase of Development, Route of Administration, and Target Disease Indication
  - 8.3.6.4. Success Protocol Analysis
- 8.3.7. HEMLIBRA(R) (Roche)
  - 8.3.7.1. Overview
  - 8.3.7.2. Development History
  - 8.3.7.3. Phase of Development, Route of Administration, and Target Disease Indication
  - 8.3.7.4. Success Protocol Analysis
- 8.3.8. Prolia(R) / Pralia(R) (Amgen)
  - 8.3.8.1. Overview
  - 8.3.8.2. Development History
  - 8.3.8.3. Phase of Development, Route of Administration, and Target Disease Indication
  - 8.3.8.4. Success Protocol Analysis
- 8.3.9. STELARA(R) (Janssen Biotech)
  - 8.3.9.1. Overview
  - 8.3.9.2. Development History
  - 8.3.9.3. Phase of Development, Route of Administration, and Target Disease Indication
  - 8.3.9.4. Success Protocol Analysis
- 8.3.10. Trulicity(R) (Eli Lilly)
  - 8.3.10.1. Overview
  - 8.3.10.2. Development History
  - 8.3.10.3. Phase of Development, Route of Administration, and Target Disease Indication
  - 8.3.10.4. Success Protocol Analysis
8.4. Conclusion

9. CLINICAL-STAGE SUBCUTANEOUS BIOLOGICS: MARKET LANDSCAPE

9.1. Chapter Overview

9.2. Clinical-stage Subcutaneous Biologics: Overall Market Overview

9.2.1. Analysis by Phase of Development
9.2.2. Analysis by Type of Biologic
9.2.3. Analysis by Type of Therapy
9.2.4. Analysis by Mechanism of Action
9.2.5. Analysis by Dosing Frequency
9.2.6. Analysis by Drug Designation
9.2.7. Analysis by Target Disease Indication
9.2.8. Analysis by Therapeutic Area

9.3. Clinical-stage Subcutaneous Biologics: List of Developers
- 9.3.1. Analysis by Year of Establishment
- 9.3.2. Analysis by Company Size
- 9.3.3. Analysis by Location of Headquarters
- 9.3.4. Most Active Developers: Analysis by Number of Clinical-stage Drugs

10. SUBCUTANEOUS FORMULATION: TECHNOLOGY LANDSCAPE

10.1. Chapter Overview
10.2. Subcutaneous Formulation: Technology Landscape
- 10.2.1. Analysis by Fundamental Principle
- 10.2.2. Analysis by Type of Molecule
- 10.2.3. Analysis by Route of Administration
- 10.2.4. Analysis by Therapeutic Area
- 10.2.5. Analysis by Key Characteristics
10.3. Subcutaneous Formulation: Technology Developers Landscape
- 10.3.1. Analysis by Year of Establishment
- 10.3.2. Analysis by Company Size
- 10.3.3. Analysis by Location of Headquarters

11. TECHNOLOGY COMPETITIVENESS ANALYSIS

11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.3. Methodology
11.4. Technology Competitiveness Analysis: Subcutaneous Formulation Technology
- 11.4.1. Subcutaneous Formulation Technology Developed by Companies based in North America (Peer Group I)
- 11.4.2. Subcutaneous Formulation Technology Developed by Companies based in Europe (Peer Group II)
- 11.4.3. Subcutaneous Formulation Technology Developed by Companies based in Asia-Pacific (Peer Group III)

12. SUBCUTANEOUS FORMULATION TECHNOLOGY PROVIDERS: COMPANY PROFILES

12.1. Chapter Overview
12.2. Technology Developers Based in North America
- 12.2.1. CD Bioparticles
  - 12.2.1.1. Company Overview
  - 12.2.1.2. Technology Portfolio
  - 12.2.1.3. Recent Developments and Future Outlook
- 12.2.2. Creative Biolabs
  - 12.2.2.1. Company Overview
  - 12.2.2.2. Technology Portfolio
  - 12.2.2.3. Recent Developments and Future Outlook
- 12.2.3. Creative BioMart
  - 12.2.3.1. Company Overview
  - 12.2.3.2. Technology Portfolio
  - 12.2.3.3. Recent Developments and Future Outlook
- 12.2.4. Pacira BioSciences
  - 12.2.4.1. Company Overview
  - 12.2.4.2. Financial Information
  - 12.2.4.3. Technology Portfolio
  - 12.2.4.4. Recent Developments and Future Outlook
- 12.2.5. The Wyss Institute
  - 12.2.5.1. Company Overview
  - 12.2.5.2. Technology Portfolio
  - 12.2.5.3. Recent Developments and Future Outlook
- 12.2.6. Xeris Biopharma
  - 12.2.6.1. Company Overview
  - 12.2.6.2. Financial Information
  - 12.2.6.3. Technology Portfolio
  - 12.2.6.4. Recent Developments and Future Outlook
12.3. Technology Developers Based in Europe
- 12.3.1. Adocia
  - 12.3.1.1. Company Overview
  - 12.3.1.2. Financial Information
  - 12.3.1.3. Technology Portfolio
  - 12.3.1.4. Recent Developments and Future Outlook
- 12.3.2. Ascendis Pharma
  - 12.3.2.1. Company Overview
  - 12.3.2.2. Financial Information
  - 12.3.2.3. Technology Portfolio
  - 12.3.2.4. Recent Developments and Future Outlook
12.4. Technology Developers Based in Asia-Pacific
- 12.4.1. Alteogen
  - 12.4.1.1. Company Overview
  - 12.4.1.2. Technology Portfolio
  - 12.4.1.3. Recent Developments and Future Outlook
- 12.4.2. Foresee Pharmaceuticals
  - 12.4.2.1. Company Overview
  - 12.4.2.2. Financial Information
  - 12.4.2.3. Technology Portfolio
  - 12.4.2.4. Recent Developments and Future Outlook

13. SUBCUTANEOUS FORMULATION TECHNOLOGIES: PARTNERSHIPS AND COLLABORATIONS

13.1. Chapter Overview
13.2. Partnership Models
13.3. Partnerships and Collaborations: Subcutaneous Formulation Technology
- 13.3.1. Analysis by Year of Partnership
- 13.3.2. Analysis by Type of Partnership
- 13.3.3. Analysis by Year and Type of Partnership
- 13.3.4. Analysis by Type of Partner
- 13.3.5. Analysis by Location of Headquarters of Partner
- 13.3.6. Analysis by Therapeutic Area
- 13.3.7. Most Active Players: Analysis by Number of Partnerships
13.4. Analysis by Geography
- 13.4.1. Intracontinental and Intercontinental Agreements
- 13.4.2. International and Local Agreements

14. SUBCUTANEOUS DRUG DELIVERY SYSTEMS: MARKET LANDSCAPE

14.1. Chapter Overview
14.2. Types of Subcutaneous Drug Delivery Systems
- 14.2.1. Large Volume Wearable Injectors
  - 14.2.1.1. Large Volume Wearable Injectors for Non-Insulin Drugs: Market Landscape
    - 14.2.1.1.1. Analysis by Status of Development
    - 14.2.1.1.2. Analysis by Type of Device
    - 14.2.1.1.3. Analysis by Usability
    - 14.2.1.1.4. Analysis by Type of Dose
    - 14.2.1.1.5. Analysis by Type of Drug Container
    - 14.2.1.1.6. Analysis by Mode of Drug Filling
    - 14.2.1.1.7. Analysis by Container Volume (mL)
    - 14.2.1.1.8. Analysis by Route of Administration
    - 14.2.1.1.9. Analysis by Mode of Injection
    - 14.2.1.1.10. Analysis by Mechanism of Action / Driving Force
    - 14.2.1.1.11. Analysis by Type of Technology
    - 14.2.1.1.12. Analysis by Availability of Connectivity Feature
    - 14.2.1.1.13. Analysis by Type of Compatible Drug
    - 14.2.1.1.14. Analysis by Compatibility with High Viscosity Drugs
    - 14.2.1.1.15. Analysis by Therapeutic Area
    - 14.2.1.1.16. Most Active Players: Analysis by Number of Large Volume Wearable Injectors for Non-Insulin Drugs
  - 14.2.1.2. Large Volume Wearable Injectors for Insulin Drugs
    - 14.2.1.2.1. Analysis by Status of Development
    - 14.2.1.2.2. Analysis by Type of Device
    - 14.2.1.2.3. Analysis by Usability
    - 14.2.1.2.4. Analysis by Type of Dose
    - 14.2.1.2.5. Analysis by Mode of Drug Filling
    - 14.2.1.2.6. Analysis by Container Volume (mL)
    - 14.2.1.2.7. Analysis by Type of Diabetes
    - 14.2.1.2.8. Analysis by Type of Combination Insulin
    - 14.2.1.2.9. Analysis by Period of Use (Days)
    - 14.2.1.2.10. Analysis by Type of Device Control Feature
    - 14.2.1.2.11. Analysis by Availability of Interoperable Device
    - 14.2.1.2.12. Analysis by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Meters (BGM) System
    - 14.2.1.2.13. Analysis by Availability of Automatic Insulin Delivery (AID) / Artificial Pancreas
    - 14.2.1.2.14. Analysis by Type of Automated Insulin Delivery (AID) Feature
    - 14.2.1.2.15. Analysis by Availability of Connectivity Feature
    - 14.2.1.2.16. Analysis by Waterproof Capabilities
    - 14.2.1.2.17. Most Active Players: Analysis by Number of Large Volume Wearable Injectors for Insulin Drugs
  - 14.2.1.3. Large Volume Drug Device Combinations for Non-Insulin Drugs: Market Landscape
    - 14.2.1.3.1. Analysis by Status of Development
    - 14.2.1.3.2. Analysis by Type of Device
    - 14.2.1.3.3. Analysis by Usability
    - 14.2.1.3.4. Analysis by Type of Dose
    - 14.2.1.3.5. Analysis by Type of Drug Container
    - 14.2.1.3.6. Analysis by Mode of Drug Filling
    - 14.2.1.3.7. Analysis by Container Volume (mL)
    - 14.2.1.3.8. Analysis by Route of Administration
    - 14.2.1.3.9. Analysis by Mode of Injection
    - 14.2.1.3.10. Analysis by Type of Compatible Drug
    - 14.2.1.3.11. Analysis by Mechanism of Action / Driving Force
    - 14.2.1.3.12. Analysis by Type of Technology
    - 14.2.1.3.13. Analysis by Therapeutic Area
    - 14.2.1.3.14. Leading Players: Analysis by Number of Drug Device Combinations for Non-Insulin Drugs
- 14.2.2. Autoinjectors
  - 14.2.2.1. Current Market Landscape
    - 14.2.2.1.1. Analysis by Stage of Development
    - 14.2.2.1.2. Analysis by Usability
    - 14.2.2.1.3. Analysis by Type of Primary Drug Container
    - 14.2.2.1.4. Analysis by Requirement of Needle
    - 14.2.2.1.5. Analysis by Volume of Container
    - 14.2.2.1.6. Analysis by Type of Dose Delivered
    - 14.2.2.1.7. Analysis by Route of Administration
    - 14.2.2.1.8. Analysis by Type of Actuation Mechanism
    - 14.2.2.1.9. Analysis by Type of Feedback Mechanism
    - 14.2.2.1.10. Analysis by Availability of Connectivity Feature
    - 14.2.2.1.11. Analysis by Target Indication
    - 14.2.2.1.12. Analysis by Type of Molecule Delivered
    - 14.2.2.1.13. Analysis by End User
    - 14.2.2.1.14. Most Active Players: Analysis by Number of Autoinjectors
- 14.2.3. Pen Injectors
  - 14.2.3.1. Current Market Landscape
    - 14.2.3.1.1. Analysis by Type of Dose
    - 14.2.3.1.2. Analysis by Storage Volume / Capacity
    - 14.2.3.1.3. Analysis by Usability
    - 14.2.3.1.4. Most Active Players: Analysis by Number of Devices
  - 14.2.3.2. Drug Device Combination Products
- 14.2.4. Needle Free Injection System
  - 14.2.4.1. Current Market Landscape
    - 14.2.4.1.1. Analysis by Actuation Mechanism
    - 14.2.4.1.2. Analysis by Route of Administration
    - 14.2.4.1.3. Analysis by Type of Formulation Administered
    - 14.2.4.1.4. Analysis by Type of Drug Delivered
    - 14.2.4.1.5. Analysis by Therapeutic Area
    - 14.2.4.1.6. Analysis by Usability
    - 14.2.4.1.7. Analysis by Type of Formulation Administered and Actuation Mechanism
- 14.2.5. Novel Drug Reconstitution Delivery Systems
  - 14.2.5.1. Current Market Landscape
    - 14.2.5.1.1. Analysis by Type of Device
    - 14.2.5.1.2. Analysis by Type of Chamber
    - 14.2.5.1.3. Analysis by Type of Device and Type of Chamber
    - 14.2.5.1.4. Analysis by Physical State of Drug
    - 14.2.5.1.5. Analysis by Container Fabrication Material
    - 14.2.5.1.6. Analysis by Volume of Container
    - 14.2.5.1.7. Analysis by Drug Class
    - 14.2.5.1.8. Analysis by Device Usability
    - 14.2.5.1.9. Analysis by Container Fabrication Material and Device Usability
    - 14.2.5.1.10. Analysis by Type of Pre-sterilized Devices
    - 14.2.5.1.11. Analysis by Type of User-sterilized Devices
    - 14.2.5.1.12. Analysis by Type of Sterilization Equipment Used
    - 14.2.5.1.13. Most Active Players: Analysis by Number of Novel Drug Reconstitution Systems Manufactured
- 14.2.6. Prefilled Syringes
  - 14.2.6.1. Current Market Landscape
    - 14.2.6.1.1. Analysis by Type of Barrel Fabrication Material
    - 14.2.6.1.2. Analysis by Number of Barrel Chambers
    - 14.2.6.1.3. Analysis by Type of Needle System
    - 14.2.6.1.4. Analysis by Volume of Syringe
    - 14.2.6.1.5. Most Active Players: Analysis by Number of Prefilled Syringes
  - 14.2.6.2. Drug Device Combination Products
- 14.2.7. Implants
  - 14.2.7.1. Current Market Landscape
    - 14.2.7.1.1. Analysis by Phase of Development
    - 14.2.7.1.2. Analysis by Therapeutic Area
    - 14.2.7.1.3. Analysis by Implant Material
    - 14.2.7.1.4. Analysis by Treatment Duration
    - 14.2.7.1.5. Analysis by Type of Delivery System
    - 14.2.7.1.6. Most Active Players: Analysis by Number of Implants
  - 14.2.7.2. Subcutaneous Implants Eluting Small Molecules

15. SUBCUTANEOUS DRUG DELIVERY SYSTEMS: PRODUCT COMPETITIVENESS ANALYSIS

15.1. Chapter Overview
15.2. Large Volume Wearable Injectors
- 15.2.1. Assumptions and Key Parameters
- 15.2.2. Methodology
- 15.2.3. Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Drugs
  - 15.2.3.1. Products Developed by Players in North America
  - 15.2.3.2. Products Developed by Players in Europe
  - 15.2.3.3. Products Developed by Players in Asia and Middle East and North Africa
- 15.2.4. Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin Drugs
  - 15.2.4.1. Products Developed by Players in North America
  - 15.2.4.2. Products Developed by Players in Europe
  - 15.2.4.3. Products Developed by Players in Asia and Middle East and North Africa
- 15.2.5. Product Competitiveness Analysis: Large Volume Drug Device Combinations for Non-Insulin Drugs
  - 15.2.5.1. Products Developed by Players in North America
  - 15.2.5.2. Products Developed by Players in Europe
  - 15.2.5.3. Products Developed by Players in Middle East and North Africa
15.3. Autoinjectors
- 15.3.1. Assumptions and Key Parameters
- 15.3.2. Methodology
- 15.3.3. Product Competitiveness Analysis: Autoinjectors
  - 15.3.3.1. Disposable Autoinjectors
  - 15.3.3.2. Reusable Autoinjectors
15.4. Needle-free Injection Systems
- 15.4.1. Assumptions and Key Parameters
- 15.4.2. Methodology
- 15.4.3. Product Competitiveness Analysis: Needle-free Injection Systems
  - 15.4.3.1. Spring-based Needle-free Injection Systems
  - 15.4.3.2. Gas-powered Needle-free Injection Systems
  - 15.4.3.3. Other Needle-free Injection Systems
15.5. Prefilled Syringes
- 15.5.1. Assumptions and Key Parameters
- 15.5.2. Methodology
- 15.5.3. Product Competitiveness Analysis: Prefilled Syringes
  - 15.5.3.1. Glass Barrel Prefilled Syringes
  - 15.5.3.2. Plastic Barrel Prefilled Syringes

16. SWOT ANALYSIS

16.1. Chapter Overview
16.2. Comparison of SWOT Factors
- 16.2.1. Strengths
- 16.2.2. Weaknesses
- 16.2.3. Opportunities
- 16.2.4. Threats

17. GLOBAL APPROVED SUBCUTANEOUS BIOLOGICS MARKET

17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global Approved Subcutaneous Biologics Market, till 2035
- 17.3.1. Roots Analysis Perspective on Market Growth
- 17.3.2. Scenario Analysis
  - 17.3.2.1. Conservative Scenario
  - 17.3.2.2. Optimistic Scenario
17.4. Key Market Segmentations

18. APPROVED SUBCUTANEOUS BIOLOGICS MARKET, BY TYPE OF BIOLOGIC

18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Approved Subcutaneous Biologics Market: Distribution by Type of Biologic, Current year and 2035
- 18.3.1. Approved Subcutaneous Biologics Market for Antibodies, till 2035
- 18.3.2. Approved Subcutaneous Biologics Market for Proteins, till 2035
- 18.3.3. Approved Subcutaneous Biologics Market for Nucleotides, till 2035
18.4. Data Triangulation and Validation

19. APPROVED SUBCUTANEOUS BIOLOGICS MARKET, BY TYPE OF THERAPY

19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Approved Subcutaneous Biologics Market: Distribution by Type of Therapy, Current year and 2035
- 19.3.1. Approved Subcutaneous Biologics Market for Monotherapy, till 2035
- 19.3.2. Approved Subcutaneous Biologics Market for Combination Therapy, till 2035
- 19.3.3. Approved Subcutaneous Biologics Market for Both Monotherapy and Combination Therapies, till 2035
19.4. Data Triangulation and Validation

20. APPROVED SUBCUTANEOUS BIOLOGICS MARKET, BY METHOD OF ADMINISTRATION

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Approved Subcutaneous Biologics Market: Distribution by Method of Administration, Current year and 2035
- 20.3.1. Approved Subcutaneous Biologics Market for Administration via Injection, till 2035
- 20.3.2. Approved Subcutaneous Biologics Market for Administration via Infusion, till 2035
- 20.3.3. Approved Subcutaneous Biologics Market for Administration via Both Injection and Infusion, till 2035
20.4. Data Triangulation and Validation

21. APPROVED SUBCUTANEOUS BIOLOGICS MARKET, BY THERAPEUTIC AREA

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Approved Subcutaneous Biologics Market: Distribution by Therapeutic Area, Current year and 2035
- 21.3.1. Approved Subcutaneous Biologics Market for Autoimmune Disorders, till 2035
- 21.3.2. Approved Subcutaneous Biologics Market for Metabolic Disorders, till 2035
- 21.3.3. Approved Subcutaneous Biologics Market for Oncological Disorders, till 2035
- 21.3.4. Approved Subcutaneous Biologics Market for Hematological Disorders, till 2035
- 21.3.5. Approved Subcutaneous Biologics Market for Inflammatory Disorders, till 2035
- 21.3.6. Approved Subcutaneous Biologics Market for Neurological Disorders, till 2035
- 21.3.7. Approved Subcutaneous Biologics Market for Bone Disorders, till 2035
- 21.3.8. Approved Subcutaneous Biologics Market for Other Disorders, till 2035
21.4. Data Triangulation and Validation

22. APPROVED SUBCUTANEOUS BIOLOGICS MARKET, BY GEOGRAPHICAL REGIONS

22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Approved Subcutaneous Biologics Market: Distribution by Geographical Regions, Current year and 2035
- 22.3.1. Approved Subcutaneous Biologics Market in North America, till 2035
- 22.3.2. Approved Subcutaneous Biologics Market in Europe, till 2035
- 22.3.3. Approved Subcutaneous Biologics Market in Asia-Pacific, till 2035
- 22.3.4. Approved Subcutaneous Biologics Market in Middle East and North Africa, till 2035
- 22.3.5. Approved Subcutaneous Biologics Market in Latin America, till 2035
22.4. Penetration-Growth (P-G) Matrix
22.5. Data Triangulation and Validation

23. APPROVED SUBCUTANEOUS BIOLOGICS MARKET, SALES FORECAST OF DRUGS

23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Drug-wise Sales Forecast
- 23.3.1. Actemra(R) / RoActemra(R)
- 23.3.2. Acthar(R) Gel / ACTHar
- 23.3.3. AIMOVIG(R)
- 23.3.4. AJOVY(R)
- 23.3.5. AMVUTTRA(R)
- 23.3.6. Aranesp(R) / NESP(R)
- 23.3.7. Basaglar(R) / Abasaglar
- 23.3.8. BENLYSTA(R)
- 23.3.9. Betaseron(R) / Betaferon(R) / EXTAVIA(R)
- 23.3.10. CABLIVI(R)
- 23.3.11. CIMZIA(R)
- 23.3.12. COSENTYX(R)
- 23.3.13. CRYSVITA(R)
- 23.3.14. DARZALEX FASPRO(R) / DARZALEX(R) SC
- 23.3.15. DUPIXENT(R)
- 23.3.16. EMGALITY(R)
- 23.3.17. Enbrel(R)
- 23.3.18. ENSPRYNG(R)
- 23.3.19. ENTYVIO(R)
- 23.3.20. Epogen(R) / Procrit(R) / Eprex(R)
- 23.3.21. EVENITY(R)
- 23.3.22. FASENRA(R)
- 23.3.23. FIASP(R)
- 23.3.24. Forteo(R) / Forsteo(R)
- 23.3.25. GATTEX(R) / Revestive(R)
- 23.3.26. Genotropin(R)
- 23.3.27. GIVLAARI(R)
- 23.3.28. G-LASTA(R) / Peglasta(R) / Neulasta(R) / GRAN(R)
- 23.3.29. Gonal-F(R)
- 23.3.30. HAEGARDA(R)
- 23.3.31. HEMLIBRA(R)
- 23.3.32. Herceptin(R) SC / HERCEPTIN(TM) HYLECTA
- 23.3.33. Hizentra(R)
- 23.3.34. Humalog(R)
- 23.3.35. HUMIRA(R)
- 23.3.36. Humulin(R)
- 23.3.37. ILARIS(R)
- 23.3.38. Kesimpta(R)
- 23.3.39. KEVZARA(R)
- 23.3.40. KINERET(R)
- 23.3.41. LANTUS(R)
- 23.3.42. LEQVIO(R)
- 23.3.43. Mircera(R)
- 23.3.44. MOUNJARO(R)
- 23.3.45. NPLATE(R)
- 23.3.46. Nucala(R)
- 23.3.47. ORENCIA(R)
- 23.3.48. OXLUMO(R)
- 23.3.49. PALYNZIQ(R)
- 23.3.50. Phesgo(R)
- 23.3.51. PLEGRIDY(R)
- 23.3.52. PRALUENT(R)
- 23.3.53. Prolia(R) / Pralia(R)
- 23.3.54. Rebif(R)
- 23.3.55. REBLOZYL(R)
- 23.3.56. REKOVELLE(R)
- 23.3.57. Repatha(R)
- 23.3.58. RITUXAN HYCELA(R) / MabThera(R) SC
- 23.3.59. RYZODEG(R) 70/30 SC
- 23.3.60. Saizen(R)
- 23.3.61. Saxenda(R)
- 23.3.62. SIMPONI(R)
- 23.3.63. Skyrizi(R)
- 23.3.64. SOLIQUA(R) 100/33
- 23.3.65. STELARA(R)
- 23.3.66. Strensiq(R)
- 23.3.67. TAKHZYRO(R)
- 23.3.68. Taltz(R)
- 23.3.69. Tecentriq(R)
- 23.3.70. TEGSEDI(R)
- 23.3.71. TEZSPIRE(R)
- 23.3.72. Toujeo(R)
- 23.3.73. TREMFYA(R)
- 23.3.74. TRESIBA(R)
- 23.3.75. Trulicity(R)
- 23.3.76. Tysabri(R)
- 23.3.77. Ultomiris(R)
- 23.3.78. Victoza(R)
- 23.3.79. Voxzogo(R)
- 23.3.80. VYVGART(R) Hytrulo
- 23.3.81. WAINUA(TM)
- 23.3.82. Xgeva(R) / RANMARK(R)
- 23.3.83. XOLAIR(R)
- 23.3.84. XULTOPHY(R)
- 23.3.85. ZEPBOUND(R)

24. APPROVED SUBCUTANEOUS BIOLOGICS MARKET, BY LEADING PLAYERS

25. GLOBAL SUBCUTANEOUS BIOLOGICS FORMULATION TECHNOLOGIES MARKET

25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Global Subcutaneous Biologics Formulation Technologies Market, till 2035
- 25.3.1. Roots Analysis Perspective on Market Growth
- 25.3.2. Scenario Analysis
  - 25.3.2.1. Conservative Scenario
  - 25.3.2.2. Optimistic Scenario
25.4. Key Market Segmentations

26. SUBCUTANEOUS BIOLOGICS FORMULATION TECHNOLOGIES MARKET, BY FUNDAMENTAL PRINCIPLE

26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Subcutaneous Biologics Formulation Technologies Market: Distribution by Fundamental Principle, Current year and 2035
- 26.3.1. Subcutaneous Biologics Formulation Technologies Market for Encapsulation Principle, till 2035
- 26.3.2. Subcutaneous Biologics Formulation Technologies Market for Complex Formation Principle, till 2035
- 26.3.3. Subcutaneous Biologics Formulation Technologies Market for Conjugation Principle, till 2035
- 26.3.4. Subcutaneous Biologics Formulation Technologies Market for Amino Acid Interaction Principle, till 2035
- 26.3.5. Subcutaneous Biologics Formulation Technologies Market for Other Principles, till 2035
26.4. Data Triangulation and Validation

27. SUBCUTANEOUS BIOLOGICS FORMULATION TECHNOLOGIES MARKET, BY END USER

27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Subcutaneous Biologics Formulation Technologies Market: Distribution by Type of End User, Current year and 2035
- 27.3.1. Subcutaneous Biologics Formulation Technologies for Pharmaceutical and Biopharmaceutical Companies, till 2035
- 27.3.2. Subcutaneous Biologics Formulation Technologies for Biotechnology Companies, till 2035
- 27.3.3. Subcutaneous Biologics Formulation Technologies for MedTech Companies, till 2035
- 27.3.4. Subcutaneous Biologics Formulation Technologies for Contract Drug Manufacturing Organizations, till 2035
- 27.3.5. Subcutaneous Biologics Formulation Technologies for Educational Institutes, till 2035
- 27.3.6. Subcutaneous Biologics Formulation Technologies for Medical Equipment Manufacturers, till 2035
- 27.3.7. Subcutaneous Biologics Formulation Technologies for Other End Users, till 2035
27.4. Data Triangulation and Validation

28. SUBCUTANEOUS BIOLOGICS FORMULATION TECHNOLOGIES MARKET, BY THERAPEUTIC AREA

28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Subcutaneous Biologics Formulation Technologies Market: Distribution by Therapeutic Area, Current year and 2035
- 28.3.1. Subcutaneous Biologics Formulation Technologies for Oncological Disorders, till 2035
- 28.3.2. Subcutaneous Biologics Formulation Technologies for Metabolic Disorders, till 2035
- 28.3.3. Subcutaneous Biologics Formulation Technologies for Ocular Disorders, till 2035
- 28.3.4. Subcutaneous Biologics Formulation Technologies for Infectious Diseases, till 2035
- 28.3.5. Subcutaneous Biologics Formulation Technologies for Autoimmune Disorders, till 2035
- 28.3.6. Subcutaneous Biologics Formulation Technologies for Neurological Disorders, till 2035
- 28.3.7. Subcutaneous Biologics Formulation Technologies for Immunological Disorders, till 2035
- 28.3.8. Subcutaneous Biologics Formulation Technologies for Other Disorders, till 2035
28.4. Data Triangulation and Validation

29. SUBCUTANEOUS BIOLOGICS FORMULATION TECHNOLOGIES MARKET, BY KEY GEOGRAPHICAL REGIONS

29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Subcutaneous Biologics Formulation Technologies Market: Distribution by Key Geographical Regions, Current year and 2035
- 29.3.1. Subcutaneous Biologics Formulation Technologies Market in North America, till 2035
- 29.3.2. Subcutaneous Biologics Formulation Technologies Market in Europe, till 2035
- 29.3.3. Subcutaneous Biologics Formulation Technologies Market in Asia-Pacific, till 2035
29.4. Penetration-Growth (P-G) Matrix
29.5. Data Triangulation and Validation

30. SUBCUTANEOUS BIOLOGICS FORMULATION TECHNOLOGIES MARKET, BY TYPE OF PAYMENT METHOD EMPLOYED

30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Subcutaneous Biologics Formulation Technologies Market: Distribution by Type of Payment Method Employed, Current year and 2035
- 30.3.1. Subcutaneous Biologics Formulation Technologies Market based on Milestone Payments, till 2035
- 30.3.2. Subcutaneous Biologics Formulation Technologies Market based on Upfront Payments, till 2035
30.4. Data Triangulation and Validation

31. SUBCUTANEOUS BIOLOGICS FORMULATION TECHNOLOGIES MARKET, BY LEADING PLAYERS

32. SUBCUTANEOUS DRUG DELIVERY SYSTEM: MARKET FORECAST

32.1. Chapter Overview
32.2. Global Large Volume Wearable Injectors Market
- 32.2.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, till 2035 (By Value)
- 32.2.2. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, till 2035 (By Volume)
- 32.2.3. Global Large Volume Wearable Injectors Market for Insulin Drugs, till 2035 (By Value)
- 32.2.4. Global Large Volume Wearable Injectors Market for Insulin Drugs, till 2035 (By Volume)
- 32.2.5. Global Autoinjectors Market
- 32.2.6. Global Needle-free Injection Systems Market
- 32.2.7. Global Novel Drug Reconstitution Systems Market
- 32.2.8. Global Prefilled Syringes Market

33. CONCLUSION

34. EXECUTIVE INSIGHTS

34.1. Chapter Overview
34.2. Company A
- 34.2.1. Company Snapshot
- 34.2.2. Interview Transcript: Founder and Chief Executive Officer
34.3. Company B
- 34.3.1. Company Snapshot
- 34.3.2. Interview Transcript: Founder and Chief Technology Officer
34.4. Company C
- 34.4.1. Company Snapshot
- 34.4.2. Interview Transcript: Chief Executive Officer & Founder
34.5. Company D
- 34.5.1. Company Snapshot
- 34.5.2. Interview Transcript: Chief Executive Officer
34.6. Company E
- 34.6.1. Company Snapshot
- 34.6.2. Interview Transcript: Chief Executive Officer
34.7. Company F
- 34.7.1. Company Snapshot
- 34.7.2. Interview Transcript: Chief Technical Officer
34.8. Company G
- 34.8.1. Company Snapshot
- 34.8.2. Interview Transcript: Vice President and Chief Scientist
34.9. Company H
- 34.9.1. Company Snapshot
- 34.9.2. Interview Transcript: Senior Portfolio Director
34.10. Company I
- 34.10.1. Company Snapshot
- 34.10.2. Interview Transcript: Managing Director
34.11. Company J
- 34.11.1. Company Snapshot
- 34.11.2. Interview Transcript: Communication Leader
34.12. Company K
- 34.12.1. Company Snapshot
- 34.12.2. Interview Transcript: Former Founder and Chief Scientific Officer, Former Vice President (Product Development) and Former Sr. Scientist Formulation
34.13. Company L
- 34.13.1. Company Snapshot
- 34.13.2. Interview Transcript:Former Chief Commercial Officer
34.14. Company M
- 34.14.1. Company Snapshot
- 34.14.2. Interview Transcript: Anonymous
34.15. Company N
- 34.15.1. Company Snapshot
- 34.15.2. Interview Transcript: Anonymous